Focus: Serina Therapeutics is a publicly traded biotechnology company founded in 1967, headquartered in Huntsville, AL, specializing in small molecules attached to polymers for neurological disorders. The company is pre-revenue with a highly experimental pipeline in early-stage development.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Serina Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Serina Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Serina Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Serina Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Serina Therapeutics, Inc. SEC Filing (Sep 1, 2026) Stock Titan
Serina Therapeutics Inc (SER-A) Stock Price and News - theglobeandmail.com
Serina Therapeutics Inc (SER-A) Stock Price and News theglobeandmail.com
Serina Therapeutics Secures $25 Million Equity Financing Facility with Roth Principal - Minichart
Serina Therapeutics Secures $25 Million Equity Financing Facility with Roth Principal Minichart
Serina Therapeutics Sets Up $25 Million Equity Purchase Facility With Roth Principal Investments - TradingView
Serina Therapeutics Sets Up $25 Million Equity Purchase Facility With Roth Principal Investments TradingView
IPO Databook: Serina Therapeutics (SER US) - Aug 2026 - Smartkarma
IPO Databook: Serina Therapeutics (SER US) - Aug 2026 Smartkarma
SER Should I Buy - Intellectia AI
SER Should I Buy Intellectia AI
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Expert insights into the development of large-volume subcutaneous drugs with permeation enhancers: A survey examining challenges, alternatives, and future directions.
Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High-Concentration Subcutaneous Biologic Drug Development.
Showing 5 of 6 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo